Herbert Smith Freehills (London)

Sebastien Moore

Herbert Smith Freehills (London)
Lawyer (Partner)

Sebastian is recognised by the legal directories as a leading patent litigator and regularly acts for clients such as Roche, Gilead, Takeda, Sanofi in UK litigation, EPO oppositions and in co-ordinating actions on a pan-European basis. He has also represented clients in two important references on SPC matters to the CJEU. Sebastian is a solicitor advocate with rights of audience in all civil proceedings in the UK. He is a member of the International Association for the Protection of Intellectual Property and an associate member of the Chartered Institute of Patent Attorneys. Sebastian is also a guest lecturer at the University of London (on the Certificate of Intellectual Property course and the LLM course in International and Comparative Patent Law) and a tutor on the Oxford University Diploma in Intellectual Property Law and Practice. Sebastian is recognised as Leading Individual in Pharmaceuticals and Biotechnology, and led the team which recently won Transatlantic IP Team of the Year 2017 at The American Lawyer Awards, and IP Team of The Year 2017 at The Lawyer Awards.

Linked authors

Herbert Smith Freehills (Brussels)
Herbert Smith Freehills (Brussels)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)
Herbert Smith Freehills (Brussels)

Articles

540 Bulletin

Kyriakos Fountoukakos, Sebastien Moore, Peter Rowland, Kristien Geeurickx, Agathe Célarié The EU Court of Justice dismisses the appeals of several manufacturers of medicines and upholds the Commission’s decision regarding a pay-for-delay infringement (Lundbeck)

137

On 25 March 2021, the Court of Justice of the EU (“CJEU”) dismissed the appeals by Lundbeck and five producers of generic medicines against the General Court’s (GC) judgments that upheld the Commission’s decision and the fines it had imposed in its first pay-for-delay infringement decision in 2013. (...)

Kyriakos Fountoukakos, Sebastien Moore, Kristien Geeurickx The EU Commission investigates for the first time a case relating to divisional patent filing and litigation strategies in the pharmaceutical sector (Teva)

343

On 4 March 2021 the EU Commission announced it has launched a formal investigation into possible anti-competitive conduct by pharmaceutical company Teva in relation to its blockbuster drug Copaxone, which is used in the treatment of multiple sclerosis. The patent for the active ingredient in (...)

Sebastien Moore, Kyriakos Fountoukakos, Mark Jephcott, Dafni Katrana, Peter Rowland The EU General Court hands down a judgement concerning an appeal brought by an undertaking and a number of generic companies against a EU Commission decision which found that the parties had breached Article 101 TFEU by agreeing to delay the market entry of a generic drug (Lundbeck)

45

On 8 September 2016 the General Court (GC) handed down its judgments in relation to the appeals brought by Lundbeck and a number of generic companies (Sun Pharma (Ranbaxy), Arrow, Generics UK, Merck and Xellia/Alpharma) against a European Commission (Commission) decision finding that the (...)

Send a message